SINOMAB BIO-B (03681) rose more than 5% again. At the time of writing, the stock was up 4.62%, trading at HK$2.04, with a turnover of HK$13.3618 million. On the news front, SINOMAB announced that preclinical research for its first-in-class anti-IL-17RB antibody, SM17, has been published in the *ERJ Open Research*. The study demonstrated that SM17 significantly improves the pathological features of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Idiopathic Pulmonary Fibrosis (IPF) through dual inhibition of the Th2/Th17 pathway and anti-fibrotic activity, supporting its potential as a transformative therapy. Dr. Rui-An Liang, Chairman, Executive Director, and CEO of SINOMAB, stated that the company is very pleased to have the preclinical research on SM17 published in *ERJ Open Research*, highlighting its potential for treating CRSwNP and IPF. These results indicate that SM17 is a highly promising potential first-in-class biologic targeting the key upstream alarmin (IL-25). By simultaneously targeting Th2 inflammation, Th17 differentiation, and fibrosis, SM17 may offer a multi-faceted treatment strategy for CRSwNP and IPF, with the potential to address the unmet needs and limitations of current therapies targeting downstream effectors.